首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Graft Complexity-Related Outcomes of Fenestrated Endografting for Abdominal Aortic Aneurysms
【24h】

Graft Complexity-Related Outcomes of Fenestrated Endografting for Abdominal Aortic Aneurysms

机译:与腹主动脉瘤的腹腔内肠道生成的接枝复杂性相关结果

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To report the outcomes of fenestrated endovascular aneurysm repair (FEVAR) and compare early and midterm results in relation to stent-graft complexity. Methods: Between August 2006 and December 2014, 141 consecutive patients (mean age 72 +/- 7.6 years, range 50-89; 120 men) were treated electively with FEVAR for short-neck, juxtarenal, or suprarenal aortic aneurysms. Forty-five patients treated with stent-grafts featuring renal-only fenestrations were assigned to group A, while 96 patients receiving additional fenestrations for the superior mesenteric and/or celiac arteries were assigned to group B. Technical success, operative mortality and morbidity, target vessel patency, endoleak, reintervention, and survival were compared between the groups. Survival, target vessel stent patency, and reintervention during follow-up were estimated by Kaplan-Meier analysis; the estimates are presented with the 95% confidence interval (CI). Results: Technical success was achieved in 135 (95.7%) patients. Overall 30-day operative mortality was 3.5% (5/141). Perioperative complications occurred in 16 (12.1%) patients. Mean follow-up was 33 +/- 23 months. Overall estimated survival was 85.1% (95% CI 79.1% to 91.1%) at 1 year and 75.8% (95% CI 68.2% to 83.5%) at 3 years. Freedom from reintervention was 90.6% (95% CI 85.6% to 95.6%) at 1 year and 79.2% (95% CI 71% to 87.5%) at 3 years. There was no statistically significant difference between the groups in terms of perioperative mortality or morbidity, endoleak, survival, target vessel patency, or reintervention. Conclusion: The use of FEVAR for juxta-and suprarenal aneurysms is associated with low 30-day mortality/morbidity and high midterm efficacy. So far, perioperative and midterm results are not affected by the use of more complex fenestrated designs.
机译:目的:报告未结发的血管内动脉瘤修复(FEVAR)的结果,并比较早期和中期导致支架 - 移植复杂性有关。方法:2014年8月至2014年12月,连续141名患者(平均年龄72 +/- 7.6岁,范围为50-89; 120名男性)与短颈,约旦或寄生主动脉动脉瘤的FEVAR选用。分配给肾功能衰落的支架移植的四十五名患者分配给A组,而96名接受过肠系膜和/或腹腔动脉的额外衰落的患者被分配给B组。技术成功,手术死亡率和发病率,目标在组之间比较血管通畅,止吐,重新烹饪和存活。通过Kaplan-Meier分析估计,在随访期间存活,目标船支架普及和重新营养;估计呈现95%置信区间(CI)。结果:135名(95.7%)患者实现了技术成功。整体30天的手术死亡率为3.5%(5/141)。围手术期并发症发生在16名(12.1%)患者中发生。平均随访33 +/- 23个月。总体估计存活率为85.1%(95%CI 79.1%至91.1%),在3年内为75.8%(95%CI 68.2%至83.5%)。从重新入侵的自由为1年的90.6%(95%CI 85.6%至95.6%),3年,79.2%(95%CI 71%至87.5%)。在围手术期死亡率或发病率,止吐剂,生存,目标血管通勤或重新入住方面,组之间没有统计学显着差异。结论:使用FEVAR for Juxta-and suprarenal动脉瘤与低30天死亡率/发病率和高中疗效相关。到目前为止,围手术期和中期结果不受利用更复杂的未结算设计的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号